{"id":1996,"date":"2025-10-01T11:44:29","date_gmt":"2025-10-01T11:44:29","guid":{"rendered":"https:\/\/cumcura.be\/?p=1996"},"modified":"2026-05-25T14:31:40","modified_gmt":"2026-05-25T14:31:40","slug":"251001-1","status":"publish","type":"post","link":"https:\/\/cumcura.be\/en\/251001-1\/","title":{"rendered":"Major breakthrough in the treatment of tenosynovial giant cell tumors (TGCT) in adults"},"content":{"rendered":"

A historic moment for patients with tenosynovial giant cell tumors. <\/strong><\/h4>\n

For the first time in Europe, a drug has been approved for the treatment of tenosynovial giant cell tumors (TGCT)<\/strong> in adults. The drug is Vimseltinib (brand name: Romvimza)<\/strong>. This is a major breakthrough for patients who previously relied almost entirely on surgery.<\/p>\n

TGCT is a rare, benign but often highly disruptive condition<\/strong> that develops in or around joints. The tumor is not malignant, but it can cause pain, swelling, stiffness, and permanent joint damage<\/strong>, leading to significant limitations in daily life. Surgery is usually the first option, but the likelihood of recurrence is high, especially for the diffuse form of TGCT. For patients who cannot undergo surgery, treatment options have been very limited until now.<\/p>\n

About Vimseltinib (Romvimza)<\/strong><\/p>\n

Vimseltinib works by blocking the CSF1 receptor<\/strong>, a protein involved in TGCT growth. The drug is taken orally in tablet form.<\/p>\n

The European Commission\u2019s<\/strong> approval is based on the results of the international MOTION phase 3 study<\/strong>. In this trial, patients with TGCT who could not undergo surgery received either vimseltinib or a placebo.<\/p>\n

Key study results:<\/strong><\/p>\n